International / English

Merck Millipore is now Merck

EB Programs: Our Grant Programs

We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why we have developed our EB Grant programs that we run on regular basis in different regions of the world. These programs allow grant recipients receive free products and services.

2016 - Europe

Recipients

  • GeneQuine Biotherapeutics (first prize), for developing novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need
  • TILT Biotherapeutics (second prize), for enabling tumor T-cell therapy with oncolytic viruses.
  • Reneuron (third prize), for developing novel stem cell therapies targeting areas of significant unmet or poorly met medical need
  • Magnus Life Science (fourth prize), for funding, building and managing companies to translate innovative, curiosity driven science into therapeutics and devices that bring significant benefits to patients

Recipients received between €25,000 and €100,000 in technologies and services to accelerate therapeutics to market. View Press Release.


2015 - Asia

Recipients

  • Beijing Biokey, for developing a monoclonal antibody for the treatment of fibriotic disease
  • Guangdong Jia Genetic Medicine Engineering Research Center, for developing novel therapies to treat cancer and autoimmune diseases
  • Hangzhou DAC Biotech, for developing antibody drug conjugates to treat cancer
  • Akeso Biopharma, for developing a pipeline of antibodies targeting cancer, cariovascular and immune diseases
  • Shanghai Mattel Biotechnology, for developing an innovative long acting fusion FVIII to treat hemophilia

Each grant recipient received 280,000 CNY in technologies and services.


2014 - USA

Recipient

  • NGM Biopharmaceuticals, for developing biologics for the treatment of cardiometabolic conditions, bile acid-related disease, and potentially other diseases resulting from manifestations of cardiometabolic abnormalities and metabolic related cancers

NGM was awarded $89K in products and services. View Announcement.

If you want to be contacted regarding our next Emerging Biotech Grant Program, please leave your details and we will contact you.

  • Funding

    Primary Need

    Lack of funding is one of the main reasons for failure of a biologic.

    Estimates vary, but some project it costs $8-10 million just to get to IND stage, another $8-10 million for Phase I, and $20-40 million for Phase II, depending on design. Phase III costs considerably more.

    Don’t let a good drug go to waste, or too much of its value to third parties, because of funding issues. There are ways to fund biotech, from biotech crowdfunding, nondilutive funding, and nonsoursive funding, to biotech grants, angel investors, venture capital and other resources.

    More >
  • Intellectual Property

    Intellectual property strategy is essential to protecting ideas and the business. Emerging biotech community members shared their insights.

    More >
  • Regulatory Guidance

    Stay the Course

    On the journey to commercialization, be sure to stay the course by understanding the global pharmaceutical regulatory landscape.

    We offer

    More >

Emerging Biotech: Stay Current

Find out more about our programs:
Grants | Events | Innovation | Agreements

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

More details about EB Programs>

WEBINAR: Venture Capital Funding: An Insider’s View

Learn more about the ABCs of venture capital including how it works and the role of a corporate venture capital.

Watch >


WEBINAR: Accelerated ADC Development with Integrated Supply Chain Solutions

Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.

Watch Now >


WEBINAR: RNA Based Therapeutics and Vaccines: Bioprocessing Technology Trends

Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.

Watch this Webinar >


WEBINAR: Managing Process Scale-up and Tech Transfer

Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.

Watch this Webinar >


Webinars On-Demand >

WHITE PAPER: 2017 Life Science Executive Summit

Establishing an open dialog within the biotech community....

Read more and download >


The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.

Read the study >

CONNECT
Contact Us

Research. Development. Production.

We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.

© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
Merck Millipore is a part of Merck.